<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">McDougall, Cameron</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Penumbra Stroke Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Currently, the only approved treatments for thromboembolus in acute stroke are the thrombolytic agents such as tPA. However, clot-removing drugs have a high risk of bleeding complications, and they are not as effective in patients with severe strokes. The Penumbra System is a novel mechanical device designed to remove stroke-associated occlusions from the large brain vessels and is approved for use in acute stroke. The system comprises an aspirating reperfusion catheter, a separator for clearing, and a thrombus removal ring that is designed to capture calcified, hard clots.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>